Kamada (KMDA) Net Cash Flow Growth (3y) (2015 - 2026)
Kamada (KMDA) Net Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Kamada | 464.05 Mn | 434.58 Mn | 22.47 Mn | 11.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.96% |
| Mar 31, 2026 | -1,737.52% |
| Dec 31, 2025 | 43.26% |
| Sep 30, 2025 | 1,455.05% |
| Jun 30, 2025 | -48.81% |
| Mar 31, 2025 | -39.60% |
| Dec 31, 2024 | 27.83% |
| Sep 30, 2024 | -21.47% |
| Jun 30, 2024 | 5.91% |
| Mar 31, 2024 | 5.74% |
| Dec 31, 2023 | -48.05% |
| Sep 30, 2023 | 281.06% |
| Jun 30, 2023 | -36.57% |
| Mar 31, 2023 | -26.01% |
| Dec 31, 2022 | -31.04% |
| Sep 30, 2022 | -92.58% |
| Jun 30, 2022 | 61.30% |
| Mar 31, 2022 | -10.12% |
| Dec 31, 2021 | -161.04% |
| Sep 30, 2021 | 281.98% |